This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Apr;59(4):659.

doi: 10.1016/j.eururo.2011.01.022. Epub 2011 Mar 1.

Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial

Dieter Jocham¹, Martin Sommerauer

Affiliations

PMID: 21414888
DOI: 10.1016/j.eururo.2011.01.022

Comment

Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial

Dieter Jocham et al. Eur Urol. 2011 Apr.

. 2011 Apr;59(4):659.

doi: 10.1016/j.eururo.2011.01.022. Epub 2011 Mar 1.

Authors

Dieter Jocham¹, Martin Sommerauer

Affiliation

¹ Universitätsklinikum, Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany. Prof.Jocham.MUL@t-online.de

PMID: 21414888
DOI: 10.1016/j.eururo.2011.01.022

No abstract available

PubMed Disclaimer

Comment on

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. de Bono JS, et al. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. Lancet. 2010. PMID: 20888992 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science